N-[5-[Methyl(propan-2-yl)amino]-2-[2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide

CAS: 1004757-96-3

Ref. 3D-EQB75796

Informação sobre produto

• Nome: N-[5-[Methyl(propan-2-yl)amino]-2-[2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide

Descrição

N-[5-[Methyl(propan-2-yl)amino]-2-[2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide (NAPQI) is a new drug that is being developed for the treatment of autoimmune and inflammatory diseases. It inhibits tumor necrosis factor alpha (TNFα), which is a cytokine involved in the immune response, leading to decreased inflammation. NAPQI also has the ability to inhibit the production of macrophage chemotactic protein 1 (MCP1), which is a chemokine involved in the inflammatory process. NAPQI can be used as a prodrug and modulates receptor activity by binding to TNFα, leading to reduced inflammation.

• Marca: Biosynth

Propriedades químicas

• Peso molecular: 506.6 g/mol
• Fórmula: C₂₅H₃₃F₃N₆O₂
• Pureza: Min. 95%